We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Routine Blood Markers Predict Heart Failure Risk in Prediabetes

By LabMedica International staff writers
Posted on 19 Mar 2026

Heart failure prevention relies on finding high-risk adults before symptoms appear, yet effective stratification remains difficult in routine care. More...

Prediabetes affects an estimated 115.2 million U.S. adults as of January 2026 and is broadly linked to cardiovascular complications. Coexisting hypertension and silent cardiac injury or stress further complicate risk assessment. A new study shows that common blood biomarkers can identify a subgroup with markedly elevated risk of heart failure.

Researchers at Johns Hopkins Medicine (Baltimore, MD, USA) led an analysis demonstrating that elevated high-sensitivity cardiac troponin I (hs-cTnI) or N-terminal pro–B-type natriuretic peptide (NT-proBNP) identifies adults with both prediabetes and hypertension who face substantially higher risk of heart failure (HF). The work, published in JAMA Cardiology on January 14, highlights a readily accessible approach using routine blood tests. The National Institutes of Health–funded investigation underscores an overlooked population that can be flagged before clinical events occur.

The investigators defined prediabetes as fasting blood glucose of 100–125 milligrams per deciliter. Subclinical myocardial injury was defined as hs-cTnI ≥6 nanograms per liter in men or ≥4 nanograms per liter in women. Subclinical cardiac stress was defined as NT-proBNP ≥125 picograms per milliliter. Hazard ratios were calculated to compare HF incidence based on biomarker status at baseline and changes over time.

Using data from the Systolic Blood Pressure Intervention Trial (SPRINT), the team analyzed 8,234 participants ages 50 and older (mean 68 years) without diagnosed diabetes (62.9% male, 37.1% female). Two analyses were performed: outcomes by baseline biomarker levels and outcomes by biomarker changes at 12 months. At baseline, 39.7% had prediabetes, 35.7% had subclinical injury, and 43.6% had subclinical stress, with a median follow-up of 3.2 years.

Participants with baseline prediabetes plus either subclinical injury or stress were overall 10 times more likely to experience HF. By comparison, those without prediabetes but with injury or stress had moderate risk increases (hazard ratios 3.28 and 3.78, respectively). Over time, individuals with prediabetes and a ≥25% rise in hs-cTnI or NT-proBNP were 3.05 and 2.39 times more likely to develop HF, compared with 2.60 and 1.66 among those without diabetes; prediabetes alone was not linked to risk change. The authors conclude that routine biomarker testing could help target preventive interventions in this group.

“We already know there’s a link between prediabetes and heart failure. But we wanted to see if additional factors, such as subclinical heart injury or stress, could elevate the risk of developing heart failure beyond prediabetes alone,” said Justin Basile Echouffo Tcheugui, M.D., Ph.D., associate professor of medicine at the Johns Hopkins University School of Medicine.

“Using heart failure biomarkers, we can identify and treat these patients who have a much higher risk of cardiovascular disease, but this also means we can look at biomarkers for other cardiovascular events. The prediabetes state is often overlooked in patients, but by defining vulnerable subpopulations, we can take preventive actions to care for patients before emergencies occur,” said Echouffo Tcheugui.

Related Links
Johns Hopkins Medicine


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The method that profiles DNA methylation in cell-free DNA from a single blood sample to detect disease signals system-wide (photo courtesy of Shutterstock)

cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample

Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more

Pathology

view channel
Image: Spatial characterization of immune–tumor interactions and treatment response across SCLC and extended phenotype models (Cristian Barrera et al, npj Precision Oncology (2026). DOI: 10.1038/s41698-025-01225-9)

AI Pathology Tool Predicts Chemotherapy Response in Small Cell Lung Cancer

Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.